{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:04:07Z","timestamp":1790816647621,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"DOI":"10.1038\/s41409-026-03032-7","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:32:25Z","timestamp":1790814745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ATG exposure in T replete transplant for hematological malignancies: Real world analysis from BMT CTN 1202"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8410-8662","authenticated-orcid":false,"given":"Madhavi","family":"Lakkaraja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Mauguen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-1491","authenticated-orcid":false,"given":"Kinga","family":"Hosszu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"McAvoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6764-1659","authenticated-orcid":false,"given":"Valerie","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8866-5319","authenticated-orcid":false,"given":"Gabrielle","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5611-7828","authenticated-orcid":false,"given":"John E.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3377-1648","authenticated-orcid":false,"given":"K. Scott","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2232-6952","authenticated-orcid":false,"given":"Jaap Jan","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"3032_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.7326\/M19-2936","volume":"172","author":"GB McDonald","year":"2020","unstructured":"McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng GS, et al. Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. Ann Intern Med. 2020;172:229\u201339.","journal-title":"Ann Intern Med"},{"key":"3032_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.4049\/jimmunol.1601100","volume":"198","author":"MS Chaudhry","year":"2017","unstructured":"Chaudhry MS, Velardi E, Malard F, van den Brink MR. Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation: Time To T Up the Thymus. J Immunol. 2017;198:40\u20136.","journal-title":"J Immunol"},{"key":"3032_CR3","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.jaci.2016.12.992","volume":"140","author":"R Admiraal","year":"2017","unstructured":"Admiraal R, de Koning CCH, Lindemans CA, Bierings MB, Wensing AMJ, Versluys AB, et al. Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation. J Allergy Clin Immunol. 2017;140:1643\u201350.e9.","journal-title":"J Allergy Clin Immunol"},{"key":"3032_CR4","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1182\/blood.2020007905","volume":"137","author":"C de Koning","year":"2021","unstructured":"de Koning C, Prockop S, van Roessel I, Kernan N, Klein E, Langenhorst J, et al. CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation. Blood. 2021;137:848\u201355.","journal-title":"Blood"},{"key":"3032_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jcyt.2020.05.005","volume":"22","author":"I van Roessel","year":"2020","unstructured":"van Roessel I, Prockop S, Klein E, Boulad F, Scaradavou A, Spitzer B, et al. Early CD4+ T cell reconstitution as predictor of outcomes after allogeneic hematopoietic cell transplantation. Cytotherapy. 2020;22:503\u201310.","journal-title":"Cytotherapy"},{"key":"3032_CR6","doi-asserted-by":"crossref","unstructured":"Bonifazi F, Rubio MT, Bacigalupo A, Boelens JJ, Finke J, Greinix H, et al. Rabbit ATG\/ATLG in preventing graft-versus-host disease after allogeneic stem cell transplantation: consensus-based recommendations by an international expert panel. Bone Marrow Transpl. 2020;55;1093\u20131102.","DOI":"10.1038\/s41409-020-0792-x"},{"key":"3032_CR7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40262-014-0214-6","volume":"54","author":"R Admiraal","year":"2015","unstructured":"Admiraal R, van Kesteren C, Jol-van der Zijde CM, van Tol MJ, Bartelink IH, Bredius RG, et al. Population pharmacokinetic modeling of Thymoglobulin((R)) in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing. Clin Pharmacokinet. 2015;54:435\u201346.","journal-title":"Clin Pharmacokinet"},{"key":"3032_CR8","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood-2016-06-721936","volume":"128","author":"R Admiraal","year":"2016","unstructured":"Admiraal R, Lindemans CA, van Kesteren C, Bierings MB, Versluijs AB, Nierkens S, et al. Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation. Blood. 2016;128:2734\u201341.","journal-title":"Blood"},{"key":"3032_CR9","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1016\/S2352-3026(17)30029-7","volume":"4","author":"R Admiraal","year":"2017","unstructured":"Admiraal R, Nierkens S, de Witte MA, Petersen EJ, Fleurke GJ, Verrest L, et al. Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis. Lancet Haematol. 2017;4:e183\u2013e91.","journal-title":"Lancet Haematol"},{"key":"3032_CR10","doi-asserted-by":"publisher","first-page":"38","DOI":"10.21037\/sci.2017.05.02","volume":"4","author":"C de Koning","year":"2017","unstructured":"de Koning C, Admiraal R, Nierkens S, Boelens JJ. Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly. Stem Cell Investig. 2017;4:38.","journal-title":"Stem Cell Investig"},{"key":"3032_CR11","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1182\/blood-2016-06-724005","volume":"128","author":"C de Koning","year":"2016","unstructured":"de Koning C, Nierkens S, Boelens JJ. Strategies before, during, and after hematopoietic cell transplantation to improve T-cell immune reconstitution. Blood. 2016;128:2607\u201315.","journal-title":"Blood"},{"key":"3032_CR12","first-page":"263.e1","volume":"31","author":"D Drozdov","year":"2025","unstructured":"Drozdov D, Kandil J, Long SE, Demorest CV, Cao Q, Lund TC, et al. Bodyweight and Absolute Lymphocyte Count-Based Dosing of Rabbit Anti-thymocyte Globulin Results in Early CD4(+) Immune Reconstitution in Patients with Inborn Errors of Metabolism Undergoing Umbilical Cord Blood Transplantation. Transpl Cell Ther. 2025;31:263.e1\u2013.e7.","journal-title":"Transpl Cell Ther"},{"key":"3032_CR13","doi-asserted-by":"publisher","first-page":"e956","DOI":"10.1016\/S2352-3026(25)00293-5","volume":"12","author":"M Scordo","year":"2025","unstructured":"Scordo M, Perales MA, Mauguen A, Lin A, Kunvarjee B, Paes Pena M, et al. Model-based antithymocyte globulin dosing in ex vivo CD34+ selected allogeneic haematopoietic cell transplantation: a single-centre, single-arm, phase 2 study. Lancet Haematol. 2025;12:e956\u2013e65.","journal-title":"Lancet Haematol"},{"key":"3032_CR14","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1016\/S2352-3026(21)00375-6","volume":"9","author":"R Admiraal","year":"2022","unstructured":"Admiraal R, Nierkens S, Bierings MB, Bredius RGM, van Vliet I, Jiang Y, et al. Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial. Lancet Haematol. 2022;9:e111\u2013e20.","journal-title":"Lancet Haematol"},{"key":"3032_CR15","doi-asserted-by":"crossref","unstructured":"Admiraal R, Nierkens S, Bierings MB, Belderbos ME, Huitema ADR, Bredius RG, et al. Improved survival with model-based dosing of anti-thymocyte globulin in pediatric hematopoietic cell transplantation. Blood Adv. 2025;9:2344\u201353.","DOI":"10.1182\/bloodadvances.2024014836"},{"key":"3032_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41409-024-02206-5","volume":"59","author":"F Barriga","year":"2024","unstructured":"Barriga F, Wietstruck A, Schulze-Schiappacasse C, Catal\u00e1n P, Sotomayor C, Z\u00fa\u00f1iga P, et al. Individualized dose of anti-thymocyte globulin based on weight and pre-transplantation lymphocyte counts in pediatric patients: a single center experience. Bone Marrow Transplant. 2024;59:473\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"3032_CR17","unstructured":"[Available from: https:\/\/biolincc.nhlbi.nih.gov\/studies\/bmt_1202\/."},{"key":"3032_CR18","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1182\/bloodadvances.2021005584","volume":"6","author":"M Lakkaraja","year":"2022","unstructured":"Lakkaraja M, Scordo M, Mauguen A, Cho C, Devlin S, Ruiz JD, et al. Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation. Blood Adv. 2022;6:1054\u201363.","journal-title":"Blood Adv"},{"key":"3032_CR19","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","volume":"2","author":"R Admiraal","year":"2015","unstructured":"Admiraal R, van Kesteren C, Jol-van der Zijde CM, Lankester AC, Bierings MB, Egberts TC, et al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2015;2:e194\u2013203.","journal-title":"Lancet Haematol"},{"key":"3032_CR20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jcyt.2023.05.012","volume":"25","author":"AG Troullioud Lucas","year":"2023","unstructured":"Troullioud Lucas AG, Lindemans CA, Bhoopalan SV, Dandis R, Prockop SE, Naik S, et al. Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis. Cytotherapy. 2023;25:977\u201385.","journal-title":"Cytotherapy"},{"key":"3032_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jcyt.2024.01.004","volume":"26","author":"M Lakkaraja","year":"2024","unstructured":"Lakkaraja M, Mauguen A, Boulad F, Cancio MI, Curran KJ, Harris AC, et al. Impact of rabbit anti-thymocyte globulin (ATG) exposure on outcomes after ex vivo T-cell-depleted hematopoietic cell transplantation in pediatric and young adult patients. Cytotherapy. 2024;26:351\u20139.","journal-title":"Cytotherapy"},{"key":"3032_CR22","doi-asserted-by":"publisher","first-page":"6003","DOI":"10.1182\/bloodadvances.2024012670","volume":"8","author":"CC Dvorak","year":"2024","unstructured":"Dvorak CC, Long-Boyle JR, Holbrook-Brown L, Abdel-Azim H, Bertaina A, Vatsayan A, et al. Effect of rabbit ATG PK on outcomes after TCR-\u03b1\u03b2\/CD19-depleted pediatric haploidentical HCT for hematologic malignancy. Blood Adv. 2024;8:6003\u201314.","journal-title":"Blood Adv"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03032-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03032-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03032-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:32:27Z","timestamp":1790814747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-03032-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":22,"alternative-id":["3032"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-03032-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"3 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JL: Consulting fees from bluebird bio, Calliditas, Equillium, Forte Biosciences, Glaxo-Smith Kline, Incyte, Ironwood, MaaT Pharma, Medexus, Mesoblast, Nestle, Sanofi, Symbio, and X4 Pharmaceuticals and royalties from aGVHD biomarker patent licensed to Viracor. JJB: Consulting (honorarium) Sobi, Sanofi, Merck, Alexion, Rocket Pharma and Papillion Biotherapeutics. DMC (chair member);honorarium from CTI and Advanced Clinical. MAP: Reports honoraria from Allogene, Bristol-Myers Squibb, Cartesian, Celgene, Incyte, Kite\/ Gilead, Merck, Miltenyi Biotec, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Ossium Health, Pierre Fabre, Sanofi, and Takeda. He serves on DSMBs for Cidara Therapeutics\/ Mundipharma and Sellas Life Sciences. He has ownership interests in Omeros and OrcaBio. He has received institutional research support for clinical trials from Allogene, Genmab, Incyte, Kite\/Gilead, Miltenyi Biotec, Novartis, and Tr1x. SAG: Research Funding: Amgen, J&J, Takeda, Celgene, Actinuum, Sanofi, Miltenyi, Kite, EUSA.Consultancy: Amgen, J&J, Takeda, Celgene, Actinuum, Sanofi. Miltenyi, Novartis, Kite, Novartis, Jazz, BMS,Crisper, EUSA Omeros.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}